Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Recombinant allergens: the present and the future.

Jutel M, Solarewicz-Madejek K, Smolinska S.

Hum Vaccin Immunother. 2012 Oct;8(10):1534-43. doi: 10.4161/hv.22064. Epub 2012 Oct 1. Review.

2.

Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

Linhart B, Valenta R.

Vaccine. 2012 Jun 19;30(29):4328-35. doi: 10.1016/j.vaccine.2011.11.011. Epub 2011 Nov 17. Review.

3.

Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.

Valenta R, Linhart B, Swoboda I, Niederberger V.

Allergy. 2011 Jun;66(6):775-83. doi: 10.1111/j.1398-9995.2011.02565.x. Epub 2011 Feb 26. Review.

4.

Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.

Focke M, Swoboda I, Marth K, Valenta R.

Clin Exp Allergy. 2010 Mar;40(3):385-97. doi: 10.1111/j.1365-2222.2009.03443.x.

PMID:
20210812
5.

Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.

Valenta R, Campana R, Marth K, van Hage M.

J Intern Med. 2012 Aug;272(2):144-57. doi: 10.1111/j.1365-2796.2012.02556.x. Review.

6.

Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.

Crameri R.

Immunol Allergy Clin North Am. 2006 May;26(2):179-89, v. Review.

PMID:
16701139
7.

Specific allergen immunotherapy for the treatment of atopic eczema.

Tam H, Calderon MA, Manikam L, Nankervis H, García Núñez I, Williams HC, Durham S, Boyle RJ.

Cochrane Database Syst Rev. 2016 Feb 12;2:CD008774. doi: 10.1002/14651858.CD008774.pub2. Review.

8.

Strategies for converting allergens into hypoallergenic vaccine candidates.

Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D, Valenta R.

Methods. 2004 Mar;32(3):313-20. Review.

PMID:
14962766
9.

Recombinant allergens: what does the future hold?

Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, Niederberger V.

J Allergy Clin Immunol. 2011 Apr;127(4):860-4. doi: 10.1016/j.jaci.2011.02.016. Review.

PMID:
21458656
10.

Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases.

Edlmayr J, Niespodziana K, Focke-Tejkl M, Linhart B, Valenta R.

Curr Top Microbiol Immunol. 2011;352:121-40. doi: 10.1007/82_2011_130. Review.

PMID:
21626347
11.

Regulation of specific immune responses by chemical and structural modifications of allergens.

Akdis CA, Blaser K.

Int Arch Allergy Immunol. 2000 Apr;121(4):261-9. Review.

PMID:
10828716
12.

Recombinant allergens for pollen immunotherapy.

Wallner M, Pichler U, Ferreira F.

Immunotherapy. 2013 Dec;5(12):1323-38. doi: 10.2217/imt.13.114. Review.

PMID:
24283843
13.

Molecular approaches for new vaccines against allergy.

Niederberger V, Valenta R.

Expert Rev Vaccines. 2006 Feb;5(1):103-10. Review.

PMID:
16451112
14.

Advances in patent applications related to allergen immunotherapy.

Silva ES, Pinheiro CS, Quintella CM, Ferreira F, C Pacheco LG, Alcântara-Neves NM.

Expert Opin Ther Pat. 2016 Jun;26(6):657-68. doi: 10.1517/13543776.2016.1170809. Epub 2016 Apr 27. Review.

PMID:
27011299
15.

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.

Valenta R, Campana R, Focke-Tejkl M, Niederberger V.

J Allergy Clin Immunol. 2016 Feb;137(2):351-7. doi: 10.1016/j.jaci.2015.12.1299. Review.

16.

Intralymphatic immunotherapy: from the rationale to human applications.

Senti G, Johansen P, Kündig TM.

Curr Top Microbiol Immunol. 2011;352:71-84. doi: 10.1007/82_2011_133. Review.

PMID:
21725898
17.

Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.

Czarnecka-Operacz M, Jenerowicz D, Silny W.

Acta Dermatovenerol Croat. 2008;16(1):19-24.

PMID:
18358104
18.

Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.

Cromwell O, Fiebig H, Suck R, Kahlert H, Nandy A, Kettner J, Narkus A.

Immunol Allergy Clin North Am. 2006 May;26(2):261-81, vii. Review.

PMID:
16701144
19.

Safety of engineered allergen-specific immunotherapy vaccines.

Focke-Tejkl M, Valenta R.

Curr Opin Allergy Clin Immunol. 2012 Oct;12(5):555-63. doi: 10.1097/ACI.0b013e328357ca53. Review.

20.

Hypoallergenic derivatives of major grass pollen allergens for allergy vaccination.

Singh MB, Bhalla PL.

Immunol Cell Biol. 2003 Feb;81(1):86-91. Erratum in: Immunol Cell Biol. 2004 Dec;82(6):653.

Supplemental Content

Support Center